カテゴリ： GlobalData, アメリカ, 企業調査

Ironwood Pharmaceuticals Inc (IRWD)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Ironwood Pharmaceuticals Inc (IRWD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9773
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：77
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Ironwood Pharmaceuticals Inc (Ironwood) is a commercial biotechnology company that discovers, develops and commercializes medicines for gastrointestinal disorders. The company’s major products include Linzess (linaclotide), an oral capsule for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) in adults; Zurampic (lesinurad) and Duzallo (lesinurad and allopurinol), for the treatment of hyperuricemia associated with gout. Ironwood also evaluates linaclotide in other indications, new formulations and in combination with other products in various GI conditions including IBS-C or CIC in pediatrics, abdominal pain associated with IBS and uncontrolled gastroesophageal reflux disease. Its other product candidates are intended for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and specialty diseases, including sickle cell disease and achalasia. Ironwood is headquartered in Cambridge, Massachusetts, the US.

Ironwood Pharmaceuticals Inc (IRWD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Nicox Enters into Research Collaboration Agreement with Ironwood Pharma 11
Nicox Enters into Agreement with Ironwood Pharma 12
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 13
Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 14
AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 15
Licensing Agreements 17
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 17
Equity Offering 18
Ironwood Pharma Plans to Raise Funds through Public Offering of Securities 18
Ironwood Pharma Raises USD201.3 Million in Public Offering of Shares 19
Ironwood Pharma Completes Partial Exercise Of Underwriter’s Option For Public Offering Of Shares For US$146 Million 21
Ironwood Pharma Completes Public Offering Of Common Stock For US$91 Million 23
Debt Offering 25
Ironwood Pharma Raises USD150 Million in Private Placement of 8.375% Notes Due 2026 25
Ironwood Pharma Raises USD335.7 Million in Private Placement of 2.25% Notes Due 2022 26
Ironwood Pharma Completes Private Placement Of Notes Due 2024 For US$175 Million 27
Ironwood Pharmaceuticals Inc – Key Competitors 29
Ironwood Pharmaceuticals Inc – Key Employees 30
Ironwood Pharmaceuticals Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Aug 06, 2018: Ironwood Pharmaceuticals provides second quarter 2018 investor update 32
May 01, 2018: Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update 37
Feb 15, 2018: Ironwood Pharmaceuticals Reports Fourth Quarter 2017 Financial Results 39
Nov 02, 2017: Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update 42
Aug 03, 2017: Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update 47
May 08, 2017: Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update 49
Feb 21, 2017: Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update 51
Corporate Communications 55
Nov 28, 2017: Ironwood Pharmaceuticals Strengthens Executive Leadership Team 55
Sep 06, 2017: Ironwood Pharmaceuticals Announces Leadership Change 56
Apr 06, 2017: Ironwood Pharmaceuticals Appoints Dr. Christopher Wright as Senior Vice President of Global Development and Chief Development Officer 57
Jan 04, 2017: Ironwood Pharmaceuticals Appoints Amy Schulman to Board of Directors 58
Government and Public Interest 59
May 01, 2018: Ironwood Pharmaceuticals Announces Intent to Separate Soluble Guanylate Cyclase Business from Commercial and Gastrointestinal Business 59
Clinical Trials 61
Jun 21, 2018: Ironwood begins two Phase III trials of IW-3718 61
Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018 62
May 23, 2018: Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease (GERD) at Digestive Disease Week 2018 64
Dec 21, 2017: Ironwood Pharmaceuticals Initiates Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease 66
Dec 04, 2017: Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects 67
Jul 20, 2017: Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease 69
May 01, 2017: Ironwood Pharmaceuticals to Present New Data for IW-1701 at Digestive Disease Week 2017 71
Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-1973 at R&D Day 2017 72
Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017 73
Other Significant Developments 74
May 01, 2018: Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action 74
Jan 08, 2017: Ironwood Pharmaceuticals Demonstrates Strong Execution on Strategy to Build Top-Performing Commercial Biotech 75
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77

List of Tables
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ironwood Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nicox Enters into Research Collaboration Agreement with Ironwood Pharma 11
Nicox Enters into Agreement with Ironwood Pharma 12
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 13
Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 14
AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 15
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 17
Ironwood Pharma Plans to Raise Funds through Public Offering of Securities 18
Ironwood Pharma Raises USD201.3 Million in Public Offering of Shares 19
Ironwood Pharma Completes Partial Exercise Of Underwriter's Option For Public Offering Of Shares For US$146 Million 21
Ironwood Pharma Completes Public Offering Of Common Stock For US$91 Million 23
Ironwood Pharma Raises USD150 Million in Private Placement of 8.375% Notes Due 2026 25
Ironwood Pharma Raises USD335.7 Million in Private Placement of 2.25% Notes Due 2022 26
Ironwood Pharma Completes Private Placement Of Notes Due 2024 For US$175 Million 27
Ironwood Pharmaceuticals Inc, Key Competitors 29
Ironwood Pharmaceuticals Inc, Key Employees 30
Ironwood Pharmaceuticals Inc, Subsidiaries 31

List of Figures
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Ironwood Pharmaceuticals Inc (IRWD)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • salesforce.com, inc.：戦略・SWOT・企業財務分析
    salesforce.com, inc. - Strategy, SWOT and Corporate Finance Report Summary salesforce.com, inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Grupa Zywiec S.A.：企業の戦略・SWOT・財務情報
    Grupa Zywiec S.A. - Strategy, SWOT and Corporate Finance Report Summary Grupa Zywiec S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • State Atomic Energy Corporation Rosatom：企業の戦略的SWOT分析
    State Atomic Energy Corporation Rosatom - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • CorMedix Inc (CRMD)：企業の財務・戦略的SWOT分析
    Summary CorMedix Inc (CorMedix) is a commercial-stage pharmaceutical company that develops and commercializes therapeutic products for prevention and treatment of cardiac, renal and infectious diseases. The company offers neutrolin, a non-antibiotic anti-infective developed as a preventative solutio …
  • Wienerberger AG：企業のM&A・事業提携・投資動向
    Wienerberger AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Wienerberger AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Kresta Holdings Limited (KRS)：企業の財務・戦略的SWOT分析
    Kresta Holdings Limited (KRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • ReShape Lifesciences Inc (RSLS)：医療機器：M&Aディール及び事業提携情報
    Summary ReShape Lifesciences Inc (ReShape), formerly known as EnteroMedics Inc is a medical device company that develops minimally invasive medical devices to treat obesity and metabolic diseases. The company develops vBloc, a therapy used in the treatment of gastrointestinal and neurometabolic dise …
  • CYBG PLC：企業の戦略・SWOT・財務情報
    CYBG PLC - Strategy, SWOT and Corporate Finance Report Summary CYBG PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Freeport-McMoRan Inc：企業のM&A・事業提携・投資動向
    Freeport-McMoRan Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Freeport-McMoRan Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Mr.Sub：企業の戦略・SWOT・財務情報
    Mr.Sub - Strategy, SWOT and Corporate Finance Report Summary Mr.Sub - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Scb Life Assurance Public Company Limited
    Scb Life Assurance Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Scb Life Assurance Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Heartland Payment Systems, Inc.：企業のM&A・事業提携・投資動向
    Heartland Payment Systems, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Heartland Payment Systems, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • Syneron Medical Ltd-医療機器分野：企業M&A・提携分析
    Summary Syneron Medical Ltd (Syneron) is an aesthetic medical device company. It designs, develops and markets aesthetic medical products. The company products target a range of non-invasive aesthetic medical procedures and address wide range of cosmetic and medical indications such as treatment of …
  • Eskom Holdings SOC Ltd：電力：M&Aディール及び事業提携情報
    Summary Eskom Holdings SOC Ltd (Eskom) is a state-owned power utility that generates, transmits and distributes electricity. It generates electricity from coal-fired, gas-fired, hydro and pumped storage power plants, and nuclear power plants, among others. The company supplies electricity to industr …
  • Mymetics Corp (MYMX)：製薬・医療：M&Aディール及び事業提携情報
    Summary Mymetics Corp (Mymetics) is a biotechnology company that develops next-generation prophylactic vaccines for infectious diseases. The company's product pipeline includes vaccine candidates that target HIV-1/AIDS, chikungunya, intranasal influenza, malaria, herpes simplex virus (HSV) and respi …
  • St. Jude Medical, Inc.：企業のM&A・事業提携・投資動向
    St. Jude Medical, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's St. Jude Medical, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Xeikon N.V.：企業の戦略的SWOT分析
    Xeikon N.V. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Polyphor AG (POLN)：製薬・医療：M&Aディール及び事業提携情報
    Summary Polyphor AG (Polyphor) is a clinical stage biopharmaceutical company that discovers and develops antibiotics and other specialty pharma products for severe or life-threatening diseases. The company offers hematopoietic stem cells for multiple myeloma patients, Pseudomonas infections and prot …
  • Circle K Stores Inc：企業の戦略・SWOT・財務情報
    Circle K Stores Inc - Strategy, SWOT and Corporate Finance Report Summary Circle K Stores Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • A. K. Capital Services Ltd (530499)：企業の財務・戦略的SWOT分析
    A. K. Capital Services Ltd (530499) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆